Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary of relevant updates from the prior week in this industry-shaping body of
Mental Health Brake: 2024 MHPAEA Regulations Put on Hold
A recent court filing offers a reprieve to health plan sponsors in their efforts to comply with final regulations issued last year under the Mental Health Parity and Addiction Equity Act (MHPAEA). In a motion to stay proceedings in a lawsuit challenging those regulations, the U.S. Departments of the Treasury, Labor, and Health and Human
Confess, Cooperate, Clean Up – DOJ’s Compliance Deal of the Decade
Let’s face it—most healthcare organizations would rather do a group root canal than voluntarily tell the government they’ve made a mistake. The phrase “self-disclosure” doesn’t exactly scream “great career move,” and the idea of dialing up DOJ to say, “Hey, we messed up!” sounds… unappealing.
But thanks to the Criminal Division’s Corporate Enforcement and Voluntary
The Forgotten Innocent: When Health Care Providers Are Wrongly Accused of Faud!
Across the country, thousands of Medicare and Medicaid health care providers dedicate their lives to caring for vulnerable populations—seniors, people with disabilities, and low-income individuals who rely on government-sponsored health care to survive. Obviously I am not telling you novel information. These providers are not faceless corporations; they are nurses, physicians, pharmacists, therapists, and administrators.
An update from the European Court of Justice on discount campaigns run by mail order pharmacies
Do discount campaigns on prescription-only medicines (POMs) run by mail order pharmacies lure patients into consuming medicinal products? The European Court of Justice (CJEU) in the case of Apothekerkammer Nordrhein (C-517/23) has held that they do not.
Following on from the AG Opinion of Advocate General Szpunar, which we provided an update on earlier in
Upcoming Webinar: Disciplinary Actions Against Hospital Pharmacies – Prevention and Mitigation
This webinar is geared specifically towards hospital staff, pharmacists, and compliance teams. I have reviewed and analyzed all California State Board of Pharmacy (“Board”) disciplinary actions against hospital pharmacies for the last five years and this is probably the most extensive and labor intense webinar that I have ever prepared for. I am looking forward
ISCAID canine pyoderma guidelines update: part 1, surface pyoderma
Our updated (from 2014) ISCAID canine pyoderma guidelines have just been published (Loeffler et Vet Derm, 2025). The whole document is a bit of a monster so I’ll break down some of the key points over the course of a few posts.
Let’s start things off with surface pyoderma, which encompasses pyotraumatic dermatitis (acute
Fedtrade® Podcast – Doug Baker, FMI – The Food Industry Association – SelectUSA Spotlight
The Fedtrade® podcast recently interviewed Doug Baker, Vice President of Industry Relations at FMI – The Food Industry Association, as part of our SelectUSA Investment Summit Spotlight series. As the food industry association, FMI works with and on behalf of the entire industry to advance a safer, healthier and more efficient consumer food supply chain. Representatives
Value and Risk of Overlapping Intellectual Property Protections
A well-orchestrated intellectual property strategy requires carefully and thoughtfully leveraging copyright, trademark, and patent laws, as highlighted by a recent decision handed down by the United Sates Court of Appeals for the Federal Circuit: CeramTec GMBH v. CoorsTek Bioceramics LLC.
Ingenico Inc. v. IOENGINE, LLC: Federal Circuit Resolves the IPR Estoppel Split
In what is certain to become a landmark decision, the Federal Circuit has resolved a long-standing question that divided patent litigators and judges alike: does IPR estoppel apply to physical systems (“system art”) described in patents or printed publications? The Court answered with a resounding “no.” See Ingenico Inc. v. IOENGINE (“Op.”). While such systems